Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen, Cytokinetics Checked With Payers Before Taking Omecamtiv Into Phase III

Executive Summary

Partnered on chronic heart failure drug omecamtiv mecarbil, Amgen and Cytokinetics took months to design a Phase III trial that would address the needs and concerns of both payers and clinicians.


Related Content

R&D Head Sean Harper On Amgen's Long-Term Investment View
Heart Failure Pipeline Review: Amgen's Omecamtiv And Merck's Vericiguat Step Up To Plate
With Phase III Failure, Cytokinetics Shelves Tirasemtiv, Pivots To ALS Backup
Amgen Focuses On Pipeline As Mature Products Face Declining Demand
Finance Watch: $50m Doubles Magenta's Funding To Improve Stem Cell Transplants
Cytokinetics Seeks ALS Success By Focusing On Lung Function
Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No
Cytokinetics Awaits Amgen's Phase III Plan After Phase II Heart Drug Success
Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval
Amgen, Cytokinetics' heart drug misses goal in Phase II study


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts